Search

Amy E. Juedes

Examiner (ID: 10106, Phone: (571)272-4471 , Office: P/1644 )

Most Active Art Unit
1644
Art Unit(s)
1644
Total Applications
1257
Issued Applications
438
Pending Applications
162
Abandoned Applications
699

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 14567401 [patent_doc_number] => 20190211307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/289095 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289095 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/289095
COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE Feb 27, 2019 Abandoned
Array ( [id] => 18389852 [patent_doc_number] => 20230158070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => COMBINATION COMPRISING ALLOGENEIC IMMUNE CELLS DEFICIENT FOR AN ANTIGEN PRESENT ON BOTH T-CELLS AND PATHOLOGICAL CELLS AND THERAPEUTIC ANTIBODY AGAINST SAID ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/965834 [patent_app_country] => US [patent_app_date] => 2019-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965834 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/965834
COMBINATION COMPRISING ALLOGENEIC IMMUNE CELLS DEFICIENT FOR AN ANTIGEN PRESENT ON BOTH T-CELLS AND PATHOLOGICAL CELLS AND THERAPEUTIC ANTIBODY AGAINST SAID ANTIGEN Jan 29, 2019 Abandoned
Array ( [id] => 14309689 [patent_doc_number] => 20190144548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => Depletion of Plasmacytoid Dendritic Cells [patent_app_type] => utility [patent_app_number] => 16/260490 [patent_app_country] => US [patent_app_date] => 2019-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16260490 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/260490
Depletion of plasmacytoid dendritic cells Jan 28, 2019 Issued
Array ( [id] => 16657699 [patent_doc_number] => 20210054335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => METHOD FOR INCREASING DENDRITIC CELL MIGRATION ABILITY, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/977320 [patent_app_country] => US [patent_app_date] => 2019-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16977320 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/977320
METHOD FOR INCREASING DENDRITIC CELL MIGRATION ABILITY, AND USE THEREOF Jan 27, 2019 Pending
Array ( [id] => 20185936 [patent_doc_number] => 12397036 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Peptide exchange protein [patent_app_type] => utility [patent_app_number] => 16/964695 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 22 [patent_no_of_words] => 21026 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964695 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/964695
Peptide exchange protein Jan 24, 2019 Issued
Array ( [id] => 16671383 [patent_doc_number] => 20210060146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => DENDRITIC CELL VACCINATION IN PARALLEL TO CHEMOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/964863 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964863 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/964863
DENDRITIC CELL VACCINATION IN PARALLEL TO CHEMOTHERAPY Jan 24, 2019 Abandoned
Array ( [id] => 14467819 [patent_doc_number] => 20190185552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1 [patent_app_type] => utility [patent_app_number] => 16/233738 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233738 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/233738
Use of regulatory T cell-specific surface protein LRIG-1 Dec 26, 2018 Issued
Array ( [id] => 14277307 [patent_doc_number] => 20190135938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => MONOCLONAL ANTIBODIES AGAINST NKG2A [patent_app_type] => utility [patent_app_number] => 16/226742 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16226742 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/226742
MONOCLONAL ANTIBODIES AGAINST NKG2A Dec 19, 2018 Abandoned
Array ( [id] => 16832149 [patent_doc_number] => 11008390 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Antibodies to TIGIT [patent_app_type] => utility [patent_app_number] => 16/228095 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 48857 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16228095 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/228095
Antibodies to TIGIT Dec 19, 2018 Issued
Array ( [id] => 17768199 [patent_doc_number] => 11400117 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Compositions and methods for inhibiting T cell exhaustion [patent_app_type] => utility [patent_app_number] => 16/221155 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 154 [patent_no_of_words] => 33370 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16221155 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/221155
Compositions and methods for inhibiting T cell exhaustion Dec 13, 2018 Issued
Array ( [id] => 16072969 [patent_doc_number] => 20200190471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => IN VITRO IMMUNE SYNAPSE SYSTEM AND METHOD OF IN VITRO EVALUATING IMMUNE RESPONSE USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/219006 [patent_app_country] => US [patent_app_date] => 2018-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16219006 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/219006
IN VITRO IMMUNE SYNAPSE SYSTEM AND METHOD OF IN VITRO EVALUATING IMMUNE RESPONSE USING THE SAME Dec 12, 2018 Abandoned
Array ( [id] => 15209847 [patent_doc_number] => 20190367610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => Compositions and Methods for Regulating CAR T Cells [patent_app_type] => utility [patent_app_number] => 16/216460 [patent_app_country] => US [patent_app_date] => 2018-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16216460 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/216460
Compositions and Methods for Regulating CAR T Cells Dec 10, 2018 Abandoned
Array ( [id] => 19651545 [patent_doc_number] => 12173316 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => Compositions and methods for improving persistence of cells for adoptive transfer [patent_app_type] => utility [patent_app_number] => 16/769634 [patent_app_country] => US [patent_app_date] => 2018-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 10035 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16769634 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/769634
Compositions and methods for improving persistence of cells for adoptive transfer Dec 4, 2018 Issued
Array ( [id] => 19763348 [patent_doc_number] => 12221627 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-11 [patent_title] => Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells [patent_app_type] => utility [patent_app_number] => 16/768930 [patent_app_country] => US [patent_app_date] => 2018-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 45 [patent_no_of_words] => 19217 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 322 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16768930 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/768930
Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells Dec 2, 2018 Issued
Array ( [id] => 18290020 [patent_doc_number] => 11618884 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-04 [patent_title] => Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof [patent_app_type] => utility [patent_app_number] => 16/763020 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 16995 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763020 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/763020
Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof Nov 12, 2018 Issued
Array ( [id] => 16870424 [patent_doc_number] => 20210163891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => GENETICALLY ENGINEERED GAMMA DELTA T CELL [patent_app_type] => utility [patent_app_number] => 16/763866 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763866 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/763866
GENETICALLY ENGINEERED GAMMA DELTA T CELL Nov 12, 2018 Abandoned
Array ( [id] => 16913932 [patent_doc_number] => 20210187024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => NK-92 Cells to Stimulate Anti-Cancer Vaccine [patent_app_type] => utility [patent_app_number] => 16/760893 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760893 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/760893
NK-92 Cells to Stimulate Anti-Cancer Vaccine Oct 30, 2018 Abandoned
Array ( [id] => 16629776 [patent_doc_number] => 20210048429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => PLZF+ REGULATORY CD8 T CELLS FOR CONTROL OF INFLAMMATION [patent_app_type] => utility [patent_app_number] => 16/758348 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758348 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/758348
PLZF+ REGULATORY CD8 T CELLS FOR CONTROL OF INFLAMMATION Oct 22, 2018 Abandoned
Array ( [id] => 13904393 [patent_doc_number] => 20190041401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => Methods of Treating Subjects having Severe and/or Persistent Asthma [patent_app_type] => utility [patent_app_number] => 16/165402 [patent_app_country] => US [patent_app_date] => 2018-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165402 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/165402
Methods of Treating Subjects having Severe and/or Persistent Asthma Oct 18, 2018 Abandoned
Array ( [id] => 14531807 [patent_doc_number] => 20190201524 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => ENHANCEMENT OF THE IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/165113 [patent_app_country] => US [patent_app_date] => 2018-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165113 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/165113
ENHANCEMENT OF THE IMMUNE RESPONSE Oct 18, 2018 Pending
Menu